Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation

In-Hospital Complications Associated With Catheter Ablation of Atrial Fibrillation in the United States Between 2000 and 2010

(2013) Abhishek Deshmukh et al.   CIRCULATION

Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature

(2013) Stefan H. Hohnloser et al.   EUROPACE

Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation

(2013) C. Eitel et al.   EUROPACE

Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis

(2013) Aref A. Bin Abdulhak et al.   EUROPACE

Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis

(2013) Rui Providência et al.   HEART

Dabigatran versus Warfarin Therapy for Uninterrupted Oral Anticoagulation During Atrial Fibrillation Ablation

(2013) WILLIAM MADDOX et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial

(2013) Jonathan P. Piccini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ablation of Atrial Fibrillation Under Therapeutic Warfarin Reduces Periprocedural Complications

(2012) Pasquale Santangeli et al.   Circulation-Arrhythmia and Electrophysiology

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society

(2012) H. Calkins et al.   EUROPACE

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPACE

Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients

(2012) T. Wilke et al.   EUROPACE

Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation

(2012) Jin-Seok Kim et al.   HEART RHYTHM

Venice Chart International Consensus Document on Atrial Fibrillation Ablation: 2011 Update

(2012) ANTONIO RAVIELE et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

Complications of atrial fibrillation ablation: when prevention is better than cure

(2011) A. Sorgente et al.   EUROPACE

Mechanisms for the initiation of human atrial fibrillation

(2009) David E. Krummen et al.   HEART RHYTHM

Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: A safe and efficacious periprocedural anticoagulation strategy

(2009) Ayman A. Hussein et al.   HEART RHYTHM

Guidelines on the diagnosis and management of acute pulmonary embolism

(2008) et al.   EUROPEAN HEART JOURNAL

A nationwide survey on the prevalence of atrioesophageal fistula after left atrial radiofrequency catheter ablation

(2008) Kasturi K. Ghia et al.   JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY